#News: We are pleased to share data from our Phase 2 trial of a neutralizing antibody in the #COVID19 outpatient setting. Read more: https://t.co/DmeWSci6W6 pic.twitter.com/HFg72XUzH4
— Eli Lilly and Company (@LillyPad) September 16, 2020
Just in: Lilly is pleased to share initial positive data from the Adaptive COVID-19 Treatment Trial (ACTT-2), conducted by @NIAIDNews. One of our medicines has potential as a treatment for hospitalized #COVID19 patients. Read more: https://t.co/fesGkDn7Qo pic.twitter.com/rkp4eg3JAm
— Eli Lilly and Company (@LillyPad) September 14, 2020
Transforming RVs into “clinical research units on wheels” to reach elderly patients for a #COVID19 clinical trial was truly a #Hoosier effort. Learn how two Indiana-based companies helped us bring our vision to life: https://t.co/oueHbn2HX2 #WeAreLilly @GovHolcomb pic.twitter.com/vKylrIZtfR
— Eli Lilly and Company (@LillyPad) August 6, 2020
The speed of our #COVID19 innovation isn’t just happening in labs. In just 30 days, Lilly employees – with help from two Indiana-based companies – transformed an RV into a “clinical research unit on wheels” to reach elderly patients: https://t.co/oueHbn2HX2 #WeAreLilly pic.twitter.com/ke1jNe8dgi
— Eli Lilly and Company (@LillyPad) August 3, 2020
Just announced: Lilly, in partnership with @NIAIDNews & others, will initiate a Phase 3 trial of one of our potential antibody treatments for the prevention of #COVID19 in long-term care facilities. Learn more: Read more: https://t.co/OQTzjG8AMQ pic.twitter.com/0O19vP9U3t
— Eli Lilly and Company (@LillyPad) August 3, 2020
Just announced: Lilly will initiate a Phase 3 clinical trial to evaluate one of our medicines as a potential treatment for hospitalized #COVID19 patients. Read more: https://t.co/crwsmvSHx5 pic.twitter.com/F3aetQyMP4
— Eli Lilly and Company (@LillyPad) June 15, 2020
New today: We've announced, with partner Junshi Biosciences, the start of a Phase 1 study for our second potential antibody treatment designed to fight #COVID19. Here's the full story: https://t.co/Rk6eNa7egX pic.twitter.com/MEqQYKxMBk
— Eli Lilly and Company (@LillyPad) June 8, 2020
Lilly scientists delivered the first doses of our potential #COVID19 antibody treatment, flown to hospitals in several U.S. cities to start the world’s first human study of this kind of therapy to fight COVID infections. #WeAreLilly pic.twitter.com/aCRrjtu4V6
— Eli Lilly and Company (@LillyPad) June 1, 2020
We continue to focus on making medicines that people count on, as our scientists and medical experts search for #COVID19 treatments. #INThisTogether #WeAreLilly pic.twitter.com/Uq5dJUXjRU
— Eli Lilly and Company (@LillyPad) May 20, 2020
New: The Central Indiana #COVID19 Community Economic Relief Fund has granted $4M to 56 organizations in Marion County. Learn more: https://t.co/spgq0I5VmN #WeAreLilly #INthistogether pic.twitter.com/OQcsyLPmlT
— Eli Lilly and Company (@LillyPad) May 14, 2020
Our ongoing work in the fight against #COVID19 includes putting our scientific R&D expertise front and center. Learn how we're battling the virus while keeping our employees safe in this new @WSJ video: https://t.co/K3A8bMD1mQ #WeAreLilly pic.twitter.com/boBIw3HClh
— Eli Lilly and Company (@LillyPad) September 15, 2020
We're sharing our Q2 2020 results today, including R&D pipeline progress to bring medicines to people to make life better. Here's the full story: https://t.co/mX6YneXh5W $LLY pic.twitter.com/BEYeNGwHSU
— Eli Lilly and Company (@LillyPad) July 30, 2020
Congratulations, @AbCelleraBio! https://t.co/ziLNUEy9h0
— Eli Lilly and Company (@LillyPad) July 29, 2020
How can the next generation of value-based arrangements put patients front and center? We explored this in our new white paper with @Prime_PBM: https://t.co/PAF9tDyPsN #WeAreLilly pic.twitter.com/sTUrG2y6Qw
— Eli Lilly and Company (@LillyPad) July 28, 2020
We’re pleased to share that today the European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a Lilly medicine for the treatment of adult patients with moderate to severe #atopicdermatitis. https://t.co/QnqVKdRtDG pic.twitter.com/hFfxQz1H0p
— Eli Lilly and Company (@LillyPad) September 18, 2020
#DYK there will be an estimated 52,890 new cases of thyroid cancer diagnosed in 2020? To learn more about a targeted therapy approved for people living with advanced RET-driven #thyroid cancers, see here: https://t.co/6PINwWi09V pic.twitter.com/2IoAq6hlPP
— Eli Lilly and Company (@LillyPad) September 17, 2020
Watch Dr. Christopher Gharibo of @NYULangone speak with Grace Whiting, president and CEO of @NA4Caregiving, about how chronic pain due to #osteoarthritis can be a source of frustration for those who suffer from it. Watch to learn more. #PainAwarenessMonth #WeAreLilly pic.twitter.com/SXcFGmfu0T
— Eli Lilly and Company (@LillyPad) September 16, 2020
Lilly is committed to providing people with effective acute treatments for #migraine that can offer pain freedom from attacks. Read about exciting new Phase 3 data presented at #PAINWeek: https://t.co/9mRgOphU3N pic.twitter.com/WqjQ9drShi
— Eli Lilly and Company (@LillyPad) September 11, 2020
Announcement: Lilly is presenting data from 20 studies across its oncology portfolio at the @myESMO Virtual Congress. Learn more about the powerful science that we’re bringing to the conference: https://t.co/p2VJbTnHry #ESMO20 pic.twitter.com/DbCmhwRk2J
— Eli Lilly and Company (@LillyPad) September 10, 2020
This #PainAwarenessMonth, Lilly is dedicated to highlighting the growing burden of chronic pain and to supporting patients with chronic pain stemming from conditions such as #osteoarthritis. #PAINWeek #WeAreLilly pic.twitter.com/Gcsz9PESP7
— Eli Lilly and Company (@LillyPad) September 9, 2020
#DYK @NEJM published two manuscripts with data from our recent trial in RET-driven cancers? We’re proud to share the results as we bring the newly approved treatment to people with certain RET-driven lung and thyroid cancer. Learn more: https://t.co/JSUuWVjdoG pic.twitter.com/wc9HyZgsDp
— Eli Lilly and Company (@LillyPad) August 27, 2020
As a founding funder of the Indianapolis eLearning Fund, the Lilly Foundation applauds @GovHolcomb for awarding $11.5 million to provide devices and internet connectivity to students in Marion County schools to support #eLearning. https://t.co/7iSnvbbGZ1
— Eli Lilly and Company (@LillyPad) August 20, 2020
We certainly miss working alongside each other, but we’re incredibly proud of the innovative work our Lilly scientists are doing to discover a potential #COVID19 treatment. #WeAreLilly https://t.co/diU4OT7mR2
— Eli Lilly and Company (@LillyPad) August 18, 2020
Breaking News: @NIAIDNews announces the start of ACTIV-3, a Phase 3 clinical trial of one of Lilly’s potential #COVID19 antibody treatments for hospitalized patients. Read more: https://t.co/HDR431b4ZK pic.twitter.com/UjhbqRT23H
— Eli Lilly and Company (@LillyPad) August 4, 2020
ICYMI: Lilly announces positive top-line results from Phase 3 OASIS-2 study for patients with moderate to severe plaque #psoriasis. https://t.co/5QqJPLVu4r pic.twitter.com/atomEgb2Fi
— Eli Lilly and Company (@LillyPad) July 23, 2020
Lilly is proud to be one of more than 20 pharmaceutical companies that has collectively invested nearly $1 billion to create the AMR Action Fund, which aims to bring 2-4 new antibiotics to patients in the next decade. #WeAreLilly https://t.co/ShaphH78Wa
— Eli Lilly and Company (@LillyPad) July 9, 2020
After a drought of treatment innovation that lasted 20+ years, advancements in our understanding of migraine have resulted in new treatments and more meaningful care approaches. While we are in the midst of a golden era for #migraine care, we can’t rest. https://t.co/jQ0tkFzMqg pic.twitter.com/LkI3Dz8UJX
— Eli Lilly and Company (@LillyPad) June 18, 2020
To provide a more comprehensive understanding of #migraine pain, Lilly explored total pain burden. Solving for migraine means more than reducing the frequency of attacks. Learn more about the data Lilly presented at #AHS2020: https://t.co/tIsTx1Hc9c pic.twitter.com/1X7F2aK8hm
— Eli Lilly and Company (@LillyPad) June 17, 2020
Lilly announces positive top-line results from Phase 3 monarchE study in high risk early #breastcancer for its CDK4 & 6 inhibitor: https://t.co/immGOKBHpl pic.twitter.com/Y1b5zzFxtz
— Eli Lilly and Company (@LillyPad) June 16, 2020
Lilly highlights the evolution of its Dermatology portfolio at the American Academy of Dermatology (AAD) Virtual Meeting Experience. Learn more: https://t.co/M8euBBoKGO #AADVMX2020 pic.twitter.com/IrIetQrAeL
— Eli Lilly and Company (@LillyPad) June 15, 2020
Thanks to everyone who joined us for the Indy Day of Solidarity – We Stand Together virtual event. If you missed it, you can watch it here: https://t.co/T6W4HMob8E #WeAreLilly pic.twitter.com/rcdwNgYB5Z
— Eli Lilly and Company (@LillyPad) June 13, 2020
As we prepare for #AADVMX2020, get to know our very own Dr. Lotus Mallbris, Lilly’s vice president of immunology development, and how her decade of experience as a physician and researcher all began. https://t.co/UxN90fzupw #WeAreLilly pic.twitter.com/HvvfxkQhvO
— Eli Lilly and Company (@LillyPad) June 12, 2020
SVP Patrik Jonsson shares his insights on what Lilly’s recent @US_FDA approval of a medicine for nr-axSpA means for patients living with this chronic condition. https://t.co/dyz6aZAXF5 pic.twitter.com/FXzrRJ8W8i
— Eli Lilly and Company (@LillyPad) June 9, 2020
A Lilly medicine has recently been approved by the @US_FDA for treating nr-axSpA. This is an important milestone for the hundreds of thousands that live with this condition. https://t.co/dyz6aZAXF5 pic.twitter.com/3IN8Vmtzpk
— Eli Lilly and Company (@LillyPad) June 8, 2020
Lilly is proud to announce that we’ve received @US_FDA approval for a medicine that treats Non-Radiographic Axial Spondyloarthritis (nr-axSpA). https://t.co/dyz6aZAXF5 pic.twitter.com/8WI6U8Ldyn
— Eli Lilly and Company (@LillyPad) June 1, 2020
We’re pleased to have presented positive data at #ASCO20 from the LIBRETTO-001 trial evaluating an approved treatment for people living with RET-driven lung and thyroid cancers. Learn more: https://t.co/eiUPUbY3Vt pic.twitter.com/au3Rc6GiSN
— Eli Lilly and Company (@LillyPad) May 30, 2020
Breaking: @US_FDA approved one of our oncology medicines for the first-line treatment of people with metastatic EGFR-mutated non-small cell #lungcancer. We’re proud to provide a new option for people living with this type of cancer. Learn more: https://t.co/APLBsCAYEw #NSCLC #FDA pic.twitter.com/WqFjppH9yu
— Eli Lilly and Company (@LillyPad) May 30, 2020
Breaking: @US_FDA approved one of our oncology medicines for the first-line treatment of people with metastatic EGFR-mutated non-small cell #lungcancer. #NSCLC #FDA pic.twitter.com/3UGurvdLTO
— Eli Lilly and Company (@LillyPad) May 29, 2020
We are thrilled to make history with the approval of a new diagnostic agent for the evaluation of patients suspected of having #Alzheimers disease: https://t.co/UsiWxZ7SFP #FDAapproval pic.twitter.com/ysYTJzYQwe
— Eli Lilly and Company (@LillyPad) May 29, 2020
#EAN2020 data highlights how preventive #migraine treatment can improve day-to-day functioning and work productivity for those living with this debilitating disease. Learn more: https://t.co/hScOF6UZgc pic.twitter.com/cJSlXESJmj
— Eli Lilly and Company (@LillyPad) May 27, 2020
We’re pleased to participate in this important model that will make insulin more affordable for U.S. seniors. Collaborations like this prove that when business and government work together, we can make a meaningful difference for patients. #InsulinSavings https://t.co/nnK4haoFyi
— Eli Lilly and Company (@LillyPad) May 26, 2020
Data from 23 studies from Lilly #Oncology will be presented at the world’s largest cancer conference, @ASCO. Learn more: https://t.co/5OtFbrPyp1 #ASCO20 pic.twitter.com/vXTuZbOxb5
— Eli Lilly and Company (@LillyPad) May 13, 2020
#DYK: The most common endocrine #cancer continues to be #thyroidcancer. And the @US_FDA recently approved a new therapy for patients living with RET-driven lung and thyroid cancers. Here’s the latest: https://t.co/6PINwWi09V pic.twitter.com/NNe2IWvCBx
— Eli Lilly and Company (@LillyPad) May 12, 2020
#LungCancer is the leading cause of cancer deaths worldwide – and the good news is a new treatment option was just approved by the @US_FDA for people living with metastatic RET-driven lung #cancer. Learn more: https://t.co/6PINwWi09V pic.twitter.com/QU7olCdRNP
— Eli Lilly and Company (@LillyPad) May 11, 2020
Keep track of our updates as we make progress against #COVID19 via our global response page. https://t.co/oOXMOFEHjJ pic.twitter.com/6IXPoZhGm0
— Lilly Trials (@LillyTrials) September 16, 2020
Speaking of different settings, more and more clinical trials are being brought directly to the participant! Read our story about how Team Lilly brought research to elderly patients. https://t.co/bj1mHYC1AL #WeAreLilly
— Lilly Trials (@LillyTrials) September 15, 2020
Clinical trials take place in different settings. Whether it be hospitals, universities, doctors' offices, community clinics, or somewhere closer to home, trials may be more accessible than you think. https://t.co/wRPRbODJ6m pic.twitter.com/eKIMfMQVYa
— Lilly Trials (@LillyTrials) September 15, 2020
#WeekendRead: Only ~13% of English speakers in the US have proficient levels of #healthliteracy, and this isn't a patient issue; it's a provider one. Read @PEHealthIT to understand how #HCPs and clinical researchers can better clarify health information: https://t.co/vmrSVS7Jkh
— Lilly Trials (@LillyTrials) September 12, 2020
Each brick in the #HerosJourneyArt project represents a unique voice, reflecting the thoughts and feelings of patients, their family and friends, caregivers, physicians, scientists and researchers. Learn more: https://t.co/6pdIDSMA0N pic.twitter.com/sMKyc5ajhu
— Lilly Trials (@LillyTrials) September 11, 2020
#FlashbackFriday: In 2016, we shared a recap from the BIO International Convention that shared insight into the "#digitalhealth revolution". A lot has changed since then, but many of those takeaways remain true. Check it out: https://t.co/wW4uhCYvQq
— Lilly Trials (@LillyTrials) September 11, 2020
Research physicians have a big impact not just on their patients, but also on their patients' loved ones. Abby Jeske, a Lilly employee, shares how her late grandfather's research physician reignited her passion in #clinicalresearch: https://t.co/nv5HDlI2Ja #TrialsTruth
— Lilly Trials (@LillyTrials) September 10, 2020
Pros of a #platformtrial:
1️⃣ You can feel like you're part of something bigger
2️⃣ The process is similar to traditional #clinicaltrials
3️⃣ If you want to try different options, it offers a consistent journeyWant to learn the cons too? Read more here: https://t.co/ybwnktod3N
— Lilly Trials (@LillyTrials) September 10, 2020
Get the latest information on our progress against #COVID19: https://t.co/mMMnpmd6yY pic.twitter.com/hOOH33K8BD
— Lilly Trials (@LillyTrials) September 8, 2020
#SundayRead: It's estimated that about 50-70% of all appointments could be replaced with teleconsultations. How might we expand some of these innovations to the clinical trial setting? Read @NewYorker to explore the pros and cons of #telehealth: https://t.co/kJohCaYdu2
— Lilly Trials (@LillyTrials) September 6, 2020
#WeekendRead: @ClinicalLeader1 tackles the issue of systemic racism, and how it impacts #clinicaltrials. As communities of color are being disproportionately impacted by #COVID19, this article and its suggested solutions are incredibly important. Read on: https://t.co/r8aTy7C1Z8
— Lilly Trials (@LillyTrials) September 5, 2020
#FridayFact: For clinical trials of #CrohnsDisease and #UlcerativeColitis, you will probably need to visit the research doctor more often than you do for your normal care. Learn more about what to expect and find resources here: https://t.co/5r6JQJdqaQ
— Lilly Trials (@LillyTrials) September 4, 2020
Want to learn more about #clinicaltrials in general? 10 more facts you should know are here: https://t.co/Cs2zv7SphH
— Lilly Trials (@LillyTrials) September 3, 2020
5 facts about #Alzheimers clinical trials:
1️⃣ Study volunteers are vital for developing treatment options
2️⃣ You don't need to have #Alz to participate
3️⃣ Most studies require a study partner
4️⃣ Ask questions
5️⃣ All studies have drawbacksLearn more: https://t.co/XMapkKT8SW
— Lilly Trials (@LillyTrials) September 3, 2020
To kick things off on our researcher #TrialsTruth series, read more about two people making in-home visits a reality with mobile nursing. https://t.co/H6snoxIUlZ
— Lilly Trials (@LillyTrials) September 2, 2020
#WeekendRead: Lack of #diversity in clinical trials is a moral, scientific, and medical issue. Read @mnt's article for a better understanding of the problem at hand, as well as what #HCPs, researchers, and the FDA should be doing to solve it: https://t.co/8E1QjUgDPy
— Lilly Trials (@LillyTrials) August 29, 2020
#FridayFact: There are 4 phases of clinical trials, and altogether, the process can take as long as 8 years. Want to learn more about what #clinicaltrials are like? Watch @CISCRP's Finding Treatments Together video for a helpful overview: https://t.co/oHS2hYpiXO
— Lilly Trials (@LillyTrials) August 28, 2020
#DYK: Lilly helped pioneer the modern age of antibiotics, beginning by manufacturing penicillin-G during World War II. Our work didn't stop there, and we are committed to bringing new medicines to the next decade: https://t.co/WG3fm6cI1v
— Lilly Trials (@LillyTrials) August 27, 2020
Greater diversity in clinical trials ensures #COVID19 treatments help diverse populations most at risk. It's crucial to reduce barriers to entry & include more minorities in research. New @politico from our chief medical and diversity officers: https://t.co/tVEaZp2PYN #WeAreLilly
— Lilly Trials (@LillyTrials) July 21, 2020
NEW BLOG: Lilly is testing the safety and efficacy of three different antibodies that may provide future options for medical care of #COVID19 patients. Learn more in our blog by Lilly's Chief Scientific Officer Dan Skovronsky: https://t.co/v2x7whj86F
— Lilly Trials (@LillyTrials) June 23, 2020
DYK 1.5 million people experience a heart attack annually in the U.S. The @US_FDA Fast Track designation for the investigation of our medicine with @boehringerus highlights the unmet needs in adults who have had a heart attack.
More information: https://t.co/XcpAwR4IJW pic.twitter.com/biKyXpc5P9
— Lilly Diabetes (@LillyDiabetes) September 15, 2020
#News: @US_FDA approved two additional doses of our #T2D medicine, providing a new option for those with evolving treatment needs. Learn more: https://t.co/gvXYsgHdYE pic.twitter.com/WUhCHGhrsA
— Lilly Diabetes (@LillyDiabetes) September 3, 2020
We’re pleased to share full results from our phase III study in adults with #HFrEF at #ESCcongress 2020 with @boehringerus. We're committed to advancing knowledge for those with #heartfailure, the leading cause of hospitalization in the U.S. Learn more: https://t.co/XiATX9R3pF pic.twitter.com/Mv4IdGS4U2
— Lilly Diabetes (@LillyDiabetes) August 29, 2020
In partnership with @boehringerus, we’re pleased to announce that our phase III study in adults with #heartfailure met its primary endpoint. With the 6.5 million adults in the U.S. affected by heart failure, we are thrilled by these positive results. https://t.co/qvWgNHomc0 pic.twitter.com/R9M008r25e
— Lilly Diabetes (@LillyDiabetes) July 30, 2020
Today, we announced the launch of Know Before the Low. The campaign aims to raise awareness about #lowbloodsugar and very low blood sugar emergencies, and encourage people with #diabetes to be prepared. Check out our Know Before the Low resources. https://t.co/vcTm6OaRMi
— Lilly Diabetes (@LillyDiabetes) June 24, 2020
We are advancing our commitment to #diabetes care with the @US_FDA approval of our new rapid-acting mealtime insulin for adults with #type1diabetes and #type2diabetes. Learn more: https://t.co/PpwQa8yac9 pic.twitter.com/Umm4aNXNH5
— Lilly Diabetes (@LillyDiabetes) June 16, 2020
This morning Project HOPE delivered 18,520 respirator masks & 20,000 surgical masks to @PGCountyOEM and @PGCCommunity! Thank you @LillyPad for donating these lifesaving supplies so we could help frontline health workers in Maryland. #COVID19 pic.twitter.com/dAzEYxZISp
— Project HOPE (@projecthopeorg) June 11, 2020
Congratulations to Christopher Otto & Dr. Janelle Sabo from @LillyPad. They helped develop Indiana’s largest COVID-19 reference lab and the state’s largest drive-through testing facility: https://t.co/ktvXugDpC8 pic.twitter.com/t7ghajXMg0
— We Work For Health (@weworkforhealth) September 8, 2020